Evidence map›Paper›PMID 39741991›Full record

ArticleGlobal health & medicine2024

Adverse reactions to mRNA COVID-19 vaccine in people with allergies in Japan.

Naoko Shoji, Suminobu Ito, Shuko Nojiri, Wataru Urasaki, Tamaki Nara, Atsushi Okuzawa, Morikuni Tobita

Abstract read
In one paragraph

Article in Global health & medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Naoko ShojiDepartment of Healthcare Innovation, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Suminobu ItoMedical Technology Innovation Center, Juntendo University, Tokyo, Japan.
Shuko NojiriDepartment of Healthcare Innovation, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Wataru UrasakiClinical Research and Trial Center, Juntendo University Hospital, Tokyo, Japan.
Tamaki NaraDepartment of Healthcare Innovation, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Atsushi OkuzawaDepartment of Healthcare Innovation, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Morikuni TobitaDepartment of Healthcare Innovation, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

mRNA vaccines emerged as a new therapeutic modality during the COVID-19 pandemic. Individuals with allergies often experience anxiety about potential adverse reactions to these vaccines. This study aims to elucidate the relationship between adverse reactions and various allergies, asthma, or atopic disorders. Data from approximately 20,000 Japanese healthcare workers participating in a prospective cohort study were analyzed. The number of vaccinated individuals was 19,792 (first dose), with systemic reactions occurring in 35.8% after the first dose and 75.3% after the second dose. Participants with allergies were categorized into groups: food and/or drug allergies (

Indexed as

asthmaatopydrug allergyfood allergyvaccine hesitancyvaccine safety

Identifiers

PMID39741991
PMCPMC11680453

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.